organization · Reporting owner
Ultragenyx Pharmaceutical Inc.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | August 10, 2021 | August 12, 2021 |
| Solid Biosciences Inc.SLDB · Entity 4915 | 10% owner | October 22, 2020 | October 30, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date August 10, 2021 · Filed August 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,400,000 |
Ending reported balance
After 2021-08-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-08-10 · Sale · Disposed 725,000 · Balance 1,475,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $64.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 2 · 2021-08-11 · Sale · Disposed 75,000 · Balance 1,400,000 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $47.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $64.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $47.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Solid Biosciences Inc.
Report date October 22, 2020 · Filed October 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,825,797 |
Reported balance
Holding disclosure · report date 2020-10-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,825,797 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2021 Filed Aug 12, 2021 21:11 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 75,000 | $45.83 | $3,437,250.00 |
DisclosureSEC source: 0001209191-21-051182 · doc4.xml · nonDerivative · entry 2 Ultragenyx Pharmaceutical Inc. · CIK 0001515673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $47.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 10, 2021 Filed Aug 12, 2021 21:11 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 725,000 | $55.44 | $40,194,000.00 |
DisclosureSEC source: 0001209191-21-051182 · doc4.xml · nonDerivative · entry 1 Ultragenyx Pharmaceutical Inc. · CIK 0001515673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,475,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $64.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 21:55 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 357,745 | $94.97 | $33,975,042.65 |
DisclosureSEC source: 0001209191-20-062733 · doc4.xml · nonDerivative · entry 2 Ultragenyx Pharmaceutical Inc. · CIK 0001515673 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.00 to $106.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 21:55 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | SaleCommon Stock | 442,255 | $105.54 | $46,675,592.70 |
DisclosureSEC source: 0001209191-20-062733 · doc4.xml · nonDerivative · entry 1 Ultragenyx Pharmaceutical Inc. · CIK 0001515673 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,557,745 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $116.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2020 Filed May 22, 2020 17:41 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | Exercise / conversionOption (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-031641 · doc4.xml · derivative · entry 2 Ultragenyx Pharmaceutical Inc. · CIK 0001515673 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2021-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 22, 2020 17:41 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | Exercise / conversionCommon Stock | 600,000 | $16.00 | $9,600,000.00 |
DisclosureSEC source: 0001209191-20-031641 · doc4.xml · nonDerivative · entry 1 Ultragenyx Pharmaceutical Inc. · CIK 0001515673 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.